|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0003873,
umls-concept:C0086045,
umls-concept:C0205210,
umls-concept:C0229671,
umls-concept:C0439849,
umls-concept:C0871261,
umls-concept:C1122087,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-6-19
|
|
pubmed:abstractText |
A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that patients develop anti-adalimumab antibodies.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-10090187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-12584368,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-15082480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-15152062,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-15389672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-15485995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-15848070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-16239380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-16385520,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-16508927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-16793840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-16905585,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-7818570,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17301106-9751087
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0003-4967
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
921-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17301106-Antibodies,
pubmed-meshheading:17301106-Antibodies, Monoclonal,
pubmed-meshheading:17301106-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17301106-Antirheumatic Agents,
pubmed-meshheading:17301106-Arthritis, Rheumatoid,
pubmed-meshheading:17301106-Drug Administration Schedule,
pubmed-meshheading:17301106-Drug Therapy, Combination,
pubmed-meshheading:17301106-Female,
pubmed-meshheading:17301106-Humans,
pubmed-meshheading:17301106-Male,
pubmed-meshheading:17301106-Methotrexate,
pubmed-meshheading:17301106-Middle Aged,
pubmed-meshheading:17301106-Prospective Studies,
pubmed-meshheading:17301106-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
|
|
pubmed:affiliation |
Jan van Breemen Institute, 1056 AB Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
